Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

brolucizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Cyclophosphamide 2848 Cisplatin 2837 Carboplatin 2635 Radiotherapy 2522 Paclitaxel 2424 Gemcitabine 2263 pembrolizumab 2099 Docetaxel 1978 Bevacizumab 1966 Fluorouracil 1660 Capecitabine 1640 Oxaliplatin 1551 Dexamethasone 1417 Nivolumab 1394 Doxorubicin 1349 Rituximab 1338 Magnetic Resonance Spectroscopy 1229 Etoposide 1198 Irinotecan 1122 Leucovorin 1096 Drug Therapy 1062 Cytarabine 1010 Pemetrexed 944 fludarabine 933 Specimen Handling 875 Vincristine 857 Prednisone 851 Lenalidomide 838 Trastuzumab 837 Cetuximab 831

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡